Reset filter
Keywords
AML ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

269 Search results.
Relevance Rating New first Old first

Differential blood count AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 14 itemgroups, 101 items, 2 languages
Itemgroups: Differential blood count, Leucocytes, Hemoglobin, Platelets, Blasts, StabkernigeQG, SegmentkernigQG, EosinophileQG, BasophileQG, MonozytenQG, LymphozytenQG, PromyelozytenQG, MyelozytenQG, MetamyelozytenQG
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Urine analysis AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 3 itemgroups, 24 items, 2 languages
Itemgroups: Urinalysis, HarnproteineQG, KreatininQG
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Adverse Event AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 2 itemgroups, 24 items, 2 languages
Itemgroups: Adverse Event, AERQG
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Concomitant Medication AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 1 itemgroup, 50 items, 2 languages
Itemgroup: Concomitant Medication
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Clinical Chemistry AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 1 itemgroup, 17 items, 2 languages
Itemgroup: Clinical Chemistry
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Death AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 1 itemgroup, 21 items, 2 languages
Itemgroup: Death
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Follow Up AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 1 itemgroup, 12 items, 2 languages
Itemgroup: Patient status
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

End of study AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 3 itemgroups, 31 items, 2 languages
Itemgroups: End of Study, Studienabbruch: verletzte Ein-Ausschlusskrit. RQG, Studienabbruch: Unerwünschte(s) Ereignis(se) RQG
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Cytogenetic and FISH Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Cytogenetic and FISH Form

- 2/11/16 - 1 form, 5 itemgroups, 31 items, 1 language
Itemgroups: Cytogenetic and FISH Form, Comment Of The Reviewer, Interphase FISH, Metaphase FISH, Comment Of The Reviewer
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)

Chemotherapy Treatment Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Chemotherapy Treatment Form

- 2/11/16 - 1 form, 4 itemgroups, 8 items, 1 language
Itemgroups: Cycle, Patient Characteristics At Start Cylce, Administration Of Treatment, Drug
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)

Agent AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 2 itemgroups, 14 items, 2 languages
Itemgroups: Medication Pazopanib, Medication Pazopanib
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Last Pazopanib AML Pazopanib NCT01361334

- 2/11/16 - 1 form, 2 itemgroups, 18 items, 2 languages
Itemgroups: Last Pazopanib, Pazopanib abgesetzt: RQG
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial